Events

Leading science and technology company Merck has welcomed new expert guidance that will harmonise the tests used in the diagnosis and treatment of endocrine disorders in children across Australia and New Zealand.

Cartherics, a company developing off-the-shelf immune stem cell therapies with lead programs in ovarian cancer and endometriosis, has unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.

Queensland Deputy Premier Jarrod Bleijie has officially unveiled the name of Translational Research Institute’s Australian-first cGMP biomedical manufacturing facility, nearing completion next door to TRI at Woolloongabba.

“The FDA clearance and USA launch of trophon3 and trophon2 Plus mark an important milestone for Nanosonics. These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades,” said Michael Kavanagh, Nanosonics CEO and President.

WEHI researchers have visualised a key protein complex in malaria parasites for the first time, uncovering a potential new target for next-generation vaccines that could help stop the disease from spreading.

Clinical-stage biotech company Noxopharm (ASX:NOX) has announced initial results from a US company testing assets from the Sofra technology platform.

"The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,” said Marc Voigt, CEO of Immutep.

Race Oncology (ASX:RAC) has announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine in relapsed or refractory acute myeloid leukaemia patients has been published in the peer-reviewed British Journal of Haematology.

Compumedics (ASX:CMP) has announced it has secured multiple Somfit sales to pharmaceutical and clinical research organisations across the US and Europe, with combined revenues from these initial transactions now approaching $2 million.

Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that CHM CDH17 has advanced to dose level 2.

AusBiotech and Medicines Australia have marked the two-year conclusion of the joint venture Cell and Gene Catalyst by celebrating its outcomes and committing to greater industry collaboration to unify the industry’s efforts and voice.

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA) has completed the acquisition of the galidesivir antiviral program from NASDAQ-listed BioCryst Pharmaceuticals.